2021 ASCO Update From the ARROW Trial: Clinical Activity and Safety of the RET Inhibitor Pralsetinib in Patients With RET Fusion-Positive Solid Tumors

0 views
June 29, 2021
Comments 0
Login to view comments. Click here to Login